Current injection evidence
Wegovy injection hair-loss rates are tied to specific trial groups
The current Novo Nordisk Wegovy prescribing information is effective June 18, 2026 and includes both injection and tablet routes. In pooled adult weight-reduction studies 2, 3, and 4, hair loss was reported in 3.3% of participants treated with the 2.4 mg weekly injection versus 1% with placebo. The label reports 4% in female and 0.9% in male Wegovy-treated participants, versus 2% in female and 0% in male placebo participants. It says hair-loss adverse reactions in injection-treated participants were associated with weight reduction. These group data do not identify the cause, pattern, severity, onset, duration, or expected recovery for one person.
- Keep the 3.3%-versus-1% result tied to the pooled 2.4 mg weekly-injection studies; it is not a universal semaglutide or compounded-product rate.
- Association with weight reduction does not prove that every episode was caused by the medicine, the amount of weight lost, nutrition, or one specific mechanism.
- The female-versus-male subgroup figures are descriptive trial data, not an individual forecast or a reason to dismiss hair loss in any patient.
Higher-dose and pediatric boundaries
Other injection findings should not be blended into one average
The same label separately reports hair loss in 5.8% of adults treated with the 7.2 mg weekly injection, 3.3% with the 2.4 mg injection, and 1% with placebo in the relevant higher-dose trials. It also reports hair loss in 4% of pediatric participants treated with the 2.4 mg injection and none receiving placebo in the pediatric trial. These are different populations and analyses. They should not be pooled, added together, or transferred to a patient whose route, presentation, age, indication, or treatment context differs.
- Do not use the higher-dose group to predict the experience of someone prescribed a different Wegovy injection presentation or strength.
- Do not transfer pediatric findings to adults or adult findings to adolescents without age-appropriate clinical interpretation.
- Trial discontinuation, interruption, or reduction data do not establish a universal response plan for new shedding.
Tablet route boundary
Wegovy tablets are legitimate labeled products, but route-specific evidence still matters
Current labeling includes once-daily Wegovy tablets for defined adult indications as well as weekly injections. The tablet safety trial is described separately, and the label says its common adverse-reaction types and frequency were similar to the main adult table. However, the hair-loss subsection provides injection-specific percentages and does not state a separate tablet-specific hair-loss rate. A clinician should therefore verify the exact route instead of treating an injection percentage as a measured tablet rate. Legitimate labeled tablets are also different from counterfeit, imported, no-prescription, or mislabeled seller claims.
- Bring the package, prescription label, route, presentation, strength, treatment timeline, and pharmacy details to the review.
- Do not claim that oral Wegovy is fake merely because Wegovy was historically discussed as an injection-only brand.
- Do not infer that a missing route-specific percentage means zero risk, proves causation, or establishes the same incidence as injection studies.
Pattern and other possible causes
Diffuse shedding, patches, breakage, and inflamed scalp findings need different assessments
Hair loss has many possible contributors. Major weight change, low protein or overall food intake, thyroid disease, iron or other nutrient concerns, illness, surgery, stress, pregnancy or postpartum changes, hormonal conditions, genetics, scalp disease, and other medicines can overlap with Wegovy care. MedlinePlus notes that medicines, stress, low-protein diets, poor nutrition, and thyroid disease can contribute to hair loss. Timing alone cannot determine the cause.
- Report smooth bald patches, scalp pain, redness, scale, drainage, scarring, broken hairs, eyebrow loss, rash, or nail changes instead of labeling every pattern routine shedding.
- Share vomiting, diarrhea, constipation, markedly reduced appetite, trouble maintaining fluids or food, rapid weight change, fatigue, dizziness, fever, bleeding, and menstrual changes.
- List prescriptions, OTC medicines, hormones, vitamins, minerals, protein products, hair supplements, alcohol, and other substances before adding another product.
Evaluation and treatment decisions
The next step is cause-focused review—not an automatic dose change or supplement bundle
The responsible clinician can review the timeline, weight-loss pace, intake, digestive symptoms, medication list, pregnancy or postpartum context, thyroid and iron history, scalp findings, and other symptoms. Examination, targeted laboratory testing, primary-care follow-up, or dermatology referral may be appropriate depending on the pattern. Testing is not automatically identical for every patient, and a supplement should not be started merely because it appears in a hair-loss advertisement.
- Do not skip, repeat, split, stop, restart, increase, decrease, or switch Wegovy based on generic online hair-loss advice.
- Do not assume biotin, iron, zinc, vitamin A, selenium, protein powders, topical medicines, or prescription hair treatments are necessary or safe without reviewing the cause, interactions, contraindications, and testing needs.
- Seek prompt assessment when hair loss is abrupt, severe, patchy, painful, scarring, accompanied by scalp inflammation, or paired with significant systemic symptoms.
Product identity and compounded care
Wegovy trial rates do not establish risk for Ozempic or compounded semaglutide
Wegovy is an FDA-approved Novo Nordisk semaglutide product with route-, presentation-, population-, and indication-specific labeling. Ozempic also contains semaglutide but has separate product records, indications, presentations, and evidence. A patient-specific compounded semaglutide preparation is not FDA-approved Wegovy or Ozempic and is not an FDA-approved generic semaglutide finished product. It may differ in concentration, inactive ingredients, container, supplies, labeling, storage, and beyond-use date.
- Bring the exact product name, route, presentation, prescription and pharmacy label, refill or lot details, storage history, and treatment timeline.
- Do not transfer Wegovy hair-loss percentages to Ozempic, a compounded vial, an additive combination, a research-use product, or an unlabeled item.
- Avoid no-prescription sellers, counterfeit products, research-use vials, and claims that shedding proves potency or faster weight loss.